Fibrobiologics, Inc. · NASDAQ:FBLG
Fibrobiologics — Investor Presentation (September 2026)
19 slides from Fibrobiologics's investor presentation, September 2026
Slide 1: Corporate Presentation
Corporate Presentation September 2026 Harnessing the Immune Modulation and Regenerative Potential of Fibroblasts to Treat and Cure Chronic Diseases
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” under applicable securities laws. Forward -looking statements include, but are not limited to, information concerning (i) plans for, and the anticipated timing of the initiation of and results from, FibroBiologics’ (“
Slide 3: FibroBiologics Highlights
FibroBiologics Highlights Untapped, differentiated Clinical Massive Market Patent Fortress cell therapy Momentum Potential Fibroblasts are the body's Currently enrolling and Fibroblast-based platform Address a $4 trillion chronic most abundant and dosing patients in a Phase technology with 270+ dise
Slide 4: Chronic Conditions Deserve More than Maintenance
Chronic Conditions Deserve More than Maintenance Despite decades of pharmaceutical innovation, chronic diseases remain uncured . 60% 90% of America’s $4T of annual of Americans live healthcare costs driven with a chronic disease by chronic disease We believe cures will come from cell therapy, gene t
Slide 5: Fibroblasts: The Body's Hidden Healing Machine
Fibroblasts: The Body’s Hidden Healing Machine As the most prevalent cell type in the human body, they orchestrate wound repair, immune response, and tissue regeneration, yet remain underutilized in medicine. Wound Healing & Repair ✓ Allogeneic — one donor treats many patients Fibroblasts are the re
Slide 6: The Allogeneic Fibroblast Platform
The Allogeneic Fibroblast Platform A versatile, scalable cell therapy engine with broad therapeutic reach Cell Sourcing Expansion Delivery Therapeutic Action Allogeneic fibroblasts are Disease indication-specific Fibroblasts are delivered to Fibroblasts act as living harvested from accessible cell s
Slide 7: Product Pipeline
Product Pipeline Discovery Phase Preclinical Phase 1 Phase 2 Phase 3 Wound Healing CYWC628 Autoimmune/Immune Modulation CYMS101 CYPS317 CYTER915 Tissue Regeneration CybroCell CYAPO913 Oncology TCB190 CYWC628 CYMS101 CYPS317 CYTER915 CybroCell CYAPO317 TBC190 Diabetic Wound Care Multiple Sclerosis Ps
Slide 8: The Disease Burden of Diabetic Foot Ulcers
The Disease Burden of Diabetic Foot Ulcers 33M+ diabetes patients develop a 70% 60% 50–68% diabetic foot ulcer (DFU) globally Recurrence rate Infection rate Increased risk of within 3 years among DFU patients mortality CRITICAL UNMET NEED • Significant shortage of FDA-approved therapies specifically
Slide 9: CYWC628 Product Candidate for Wound Healing
CYWC628 Product Candidate for Wound Healing 1. Use of spheroids instead of single cells, containing 1,000 – 3,000 fibroblasts 2. Spheroid attachment and migration on chronic wound surface 6 Hours post administration 3. Release of all necessary chemokines, cytokines, and growth factors necessary to i
Slide 10: CYWC628 Significantly Improved Wound Closure Rate in Animal Models
CYWC628 Significantly Improved Wound Closure Rate in Animal Models Multiple Administration Comparison to FDA approved Grafix and Control Multiple administration of Grafix and CYWC628 Percent Change in Wound Area Post Treatment 1st 2nd dose 3rd dose 4th dose 100 Control dose Percent of Wound Area 80
Slide 11: CYWC628 Phase I/II Clinical Trial Ongoing
CYWC628 Phase I/II Clinical Trial Ongoing ~120 3 12 wks 6 mo Key Design Features Patients Arms Treatment Follow-Up Randomized controlled design with SoC comparator arm Low and high dose – enables dose selection for Phase 3 Screening Run-In (2 weeks) Refractory wounds only – meaningful, hard-to-treat
Slide 12: Psoriasis Unmet Medical Needs
Psoriasis Unmet Medical Needs Global prevalence of Psoriasis at 123 million worldwide • US prevalence at 7.5 million Significant lifestyle and psychological impact on patients • Mild to severe disease progression impacting patient QoL • Associated with considerable comorbidities Lack of disease-modi
Slide 13: Significant Improvement in Chronic Relapse Psoriasis Model
Significant Improvement in Chronic Relapse Psoriasis Model Durability of a single administration of PSY317 4 IMQ+Control (D24) 4 IMQ+Control (D24) 4 IMQ+Control (D24) IMQ+HDF (D24) IMQ+HDF (D24) IMQ+HDF (D24) 3 3 3 Erythema score Thickness score Scaling score 2 2 2 1 1 ** 1 **** * *** ** *** ** 0 0
Slide 14: Reduction of Pro-inflammatory Cytokines in Psoriasis Skin Lesions
Reduction of Pro-inflammatory Cytokines in Psoriasis Skin Lesions IL-23 TNF-⍺ IL-12p70 These are the same 3 cytokines targeted by monoclonal antibodies currently approved: • IL-23 inhibitors: Guselkumab (Tremfya), Tildrakizumab (Ilumya, Ilumetri), Risankizumab (Skyrizi) • TNF-alpha inhibitors: Adali
Slide 15: Competitive Landscape Psoriasis
Competitive Landscape Psoriasis FibroBiologics IL-17 Inhibitors IL-23 Inhibitors IL-12/23 Inhibitor TNF Inhibitors Criteria CYPS317 e.g., Cosentyx, Bimzelx e.g., Tremfya, Skyrizi Stelara (dual IL-12/23) e.g., Humira, Remicade Disease-Modifying Potential (Durable remission of psoriasis) Cytokine Targ
Slide 16: Additional Pipeline & Early-Stage Research Projects
Additional Pipeline & Early-Stage Research Projects PRECLINICAL PRECLINICAL EARLY RESEARCH EARLY RESEARCH Degenerative Human Multiple Sclerosis Cancer Disc Disease Longevity Fully characterized HDF subtype Fibroblast-based artificial thymic Exploratory research into the HDFs reduce inflammation with
Slide 17: Company Leadership
Company Leadership Pete O’Heeron, MSHA Hamid Khoja, Ph.D. Jason Davis, CPA (Founder, Chairman/CEO) (CSO) (CFO) • Leads an operational investment group which • 20+ years of clinical and product • 20+ years of corporate finance with both identifies early-stage opportunities in the development. publicl
Slide 18: Advisors
Advisors Board of Directors Scientific Advisory Board
Slide 19: Contact
Contact: Russo Partners fibrobiologicsir@russopr.com
FibroBiologics — Investor Presentation (September 2026) on 6ix